Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

医学 奥西默替尼 佐剂 肿瘤科 阶段(地层学) 非小细胞肺癌 内科学 肺癌 疾病 癌症 癌症研究 表皮生长因子受体 埃罗替尼 古生物学 A549电池 生物
作者
Thomas John,Christian Grohé,Jonathan W. Goldman,Terufumi Kato,К. К. Лактионов,Laura Bonanno,Marcello Tiseo,Margarita Majem,Manuel Dómine,Myung‐Ju Ahn,M. Pérol,Ryan J. Hartmaier,Jacqulyne Robichaux,Preetida J. Bhetariya,Aleksandra Markovets,Yuri Rukazenkov,Caitlin Muldoon,Roy S. Herbst,Masahiro Tsuboi,Yi‐Long Wu
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 8005-8005 被引量:19
标识
DOI:10.1200/jco.2024.42.16_suppl.8005
摘要

8005 Background: Osimertinib (osi) is a third-generation, central nervous system-active EGFR-TKI, that potently and selectively inhibits EGFR-TKI sensitizing and EGFR T790M resistance mutations. Adj osi (3 years [yrs]) is recommended for resected EGFRm stage IB–IIIA NSCLC, based on significant improvements in disease-free survival (DFS) and overall survival (OS) in the Phase III ADAURA study (NCT02511106). A trend towards an increased DFS event rate beyond 3 yrs suggests some pts may benefit from longer adj osi treatment (tx). We explored if plasma ctDNA-based, tumor-informed MRD could predict disease recurrence. Methods: Eligible pts (≥18 yrs [≥20 in Japan/Taiwan], WHO PS 0/1 with completely resected EGFRm [Ex19del/L858R] stage IB, II or IIIA [AJCC 7th edition] NSCLC) were randomized 1:1 to osi 80 mg once daily or placebo (pbo) until disease recurrence, tx completion (up to 3 yrs), or a discontinuation criterion was met. Personalized MRD panels (RaDaR, NeoGenomics) were used, comprised of ≤50 tumor-specific variants, based on whole exome sequencing of resected tumor tissue (variants identified in germline DNA removed). Plasma sample collection: baseline (BL; at randomization surgery and adj Ctx, if received), on tx (every 12 weeks [wks]), tx discontinuation, and post-tx completion (wk 12, wk 24, then every 24 wks until 5 yrs). Plasma samples were analyzed for detection of ctDNA (MRD+). Molecular recurrence or DFS (MRD/DFS) was defined as time from randomization to post-BL MRD+, disease recurrence, or death and was compared across arms. DFS was investigator-assessed. Results: Of 682 pts randomized, 245 (36%) had samples required to produce MRD panels, which were evaluable for 220 (32%) pts across both arms. In the osi vs pbo arms, 5/112 (4%) vs 13/108 (12%) pts were MRD+ at BL; 4/5 pts became MRD– during osi tx vs 0/13 pts on pbo. On tx, MRD detection had clinical sensitivity of 65% (62 MRD+/96 DFS+), specificity of 95% (118 MRD–/124 DFS–) and preceded a DFS event by a median (95% CI) of 4.7 (2.2, 5.6) months (mos) across both arms. Median follow-up time from randomization was 44.2 (95% CI 42.4, 49.1) and 19.1 (95% CI 11.1, 28.3) mos for osi and pbo arms, respectively. Overall, 86% (95% CI 78, 92) vs 36% (95% CI 27, 45) pts in the osi vs pbo arms were MRD/DFS event free at 36 mos (HR: 0.23; 95% CI 0.15, 0.36). MRD/DFS events in the osi arm were detected at any time post-BL in 28 (25%) pts, of whom 19/28 (68%) had events post-adj osi. Most (11/19 [58%]) MRD/DFS events detected occurred within 12 mos of osi tx completion. Conclusions: MRD+ preceded DFS events in most pts with a median lead time of 4.7 mos across both arms. MRD– was maintained for most pts during adj osi tx with the majority of MRD/DFS events occurring after osi tx completion. MRD detection could potentially identify a subset of pts likely to benefit from longer adj osi. Clinical trial information: NCT02511106 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
郝靖儿完成签到 ,获得积分10
刚刚
maoweicao发布了新的文献求助10
刚刚
1秒前
2秒前
Monroe完成签到 ,获得积分10
2秒前
柠栀给柠栀的求助进行了留言
2秒前
2秒前
3秒前
韩小青完成签到,获得积分10
3秒前
4秒前
ren完成签到,获得积分10
5秒前
luo完成签到,获得积分10
5秒前
5秒前
不弃发布了新的文献求助10
7秒前
ubless607的应助被Green采纳,获得10
7秒前
7秒前
搞怪的芾完成签到,获得积分10
8秒前
8秒前
兜里面有怪兽完成签到,获得积分10
9秒前
9秒前
晨昏蒙影完成签到 ,获得积分10
10秒前
一秋一年完成签到,获得积分10
10秒前
maoweicao完成签到,获得积分10
10秒前
swslgd完成签到,获得积分10
11秒前
13秒前
利妥昔单抗n完成签到,获得积分10
13秒前
长脑子的怼怼完成签到 ,获得积分10
14秒前
yyy完成签到 ,获得积分10
14秒前
15秒前
自然自行车完成签到,获得积分10
15秒前
jiangjiang完成签到,获得积分10
16秒前
神奇高乐高完成签到 ,获得积分10
17秒前
畅快季节完成签到,获得积分20
17秒前
王木木完成签到 ,获得积分10
18秒前
18秒前
cccxxx完成签到,获得积分10
18秒前
小飞完成签到,获得积分10
18秒前
19秒前
20秒前
嘟嘟豆806完成签到 ,获得积分0
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190438
求助须知:如何正确求助?哪些是违规求助? 9577668
关于积分的说明 21853638
捐赠科研通 7789450
什么是DOI,文献DOI怎么找? 3436407
关于科研通互助平台的介绍 2560224
邀请新用户注册赠送积分活动 2483032